Digital health, biotech and the metaverse

Updated: Apr 27

Season 02: episode 03

In the first episode of March, GOLD talks to Liz Ashall-Payne, founder of ORCHA, a company that curates libraries of digital health apps for patients and healthcare professionals. She discusses the growing patient appetite for apps, the education that is needed for healthcare professionals to ensure wider adoption and early considerations for pharma companies wishing to develop these solutions. 

In addition, GOLD’s Assistant Editor Isabel O’Brien speaks to Dario Safaric, founder of the 'NEXT Pharma' conferences, about the upcoming ‘Next Normal’ event (8-10 March), the topics that are important in the industry right now and pharma’s future in the metaverse. Plus, Helena and Marc round up some of the pharma news from the last week, focusing on Ukraine, COVID-19 vaccines and a new biotech development.

A little more on GOLD's guests...


Liz Ashall-Payne is the co-founder and CEO of ORCHA. A trained speech and language therapist, for almost 20 years Liz led NHS transformation programmes. She founded ORCHA in 2015, after being amazed by possibilities of digital health and how it allowed clinicians to be able to help several patients at once. She has been selected as a Tech Trailblazer by the BIMA 100, picked as a Healthcare IT Leader by the HIMSS Future 50, named Entrepreneur of the Year by the British Chamber of Commerce and has featured within the LDC top 50.

Dario Safaric is the founder and chairman of the NEXT Pharma Summit. He produces online and in-person events for pharmaceutical professionals, hosting commercial, marketing, sales, digital and patient engagement speakers and keynotes. Two events lie ahead this year: ‘Next Normal’ that will take place virtually on 8 – 10 March and ‘Next 2022’ that will take place in Dubrovnik on 17 –19 May. He hopes his events address a very simple question: Where to NEXT?

Additional resources


If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:

Click here to subscribe to the weekly newsletter for more insights from GOLD.